Upcoming FDA advisory committee meetings are expected to revisit post-independence governance questions, with specific attention on meetings involving Replimune and Capricor. Coverage also notes that peptide review topics will test the influence of Makary-era dynamics. While advisory committees do not decide regulatory outcomes, agenda-level scrutiny can influence how data packages are assessed and how contentious evidence is debated before decision-makers. For sponsors, the message is that review trajectories may remain politically and procedurally sensitive. For the industry, the operational takeaway is timing risk: sponsors preparing for advisory committee discussions may need to sharpen endpoints, safety narratives, and data integrity explanations in anticipation of broader process concerns.